ONCONASE maker announces move toward completion of IIIB mesothelioma clinical trials

11

Jun
2007

Alfacell announced its third-quarter financial results with optimism about its chemotherapy drug Onconase, which is in the process of completing IIIB clinical trials for the treatment of inoperable mesothelioma, a rare form of cancer caused by asbestos exposure. In addition to progress on the clinical trial for mesothelioma, the company is also moving toward Phase II clinical trials for the use of Onconase in the treatment of other cancers. Onconase has also been touted as a potential chemopreventive agent for mesothelioma, although clinical validation is still needed.

email this post print this page permanent link

Related News

Baron & Budd, P.C.:
Since 1977, the law firm of Baron & Budd, P.C. has championed the rights of people and communities harmed by corporate misconduct. With over 50 attorneys and offices in Texas, California, and Louisiana, Baron & Budd enjoys a national reputation as a leader of the plaintiffs’ bar. The firm represents individuals with mesothelioma and other diseases caused by asbestos and injuries caused by other toxic substances and pharmaceuticals. The firm also represents water authorities seeking clean-up costs for drinking water contamination; securities investors and governmental entities defrauded by corporate wrongdoing; and consumers. For more information about Baron & Budd, call 800-222-2766 or contact us via our secure form.

 
Other Offices:
  • Baton Rouge, LA
  • Canton, NY
  • Beverly Hills, CA
  • Austin, TX
Main Office:
3102 Oak Lawn Avenue, Suite 1100
Dallas, TX 75219
For nearly 30 years, the law firm of Baron & Budd, P.C. has fought to safeguard the rights of mesothelioma victims and their families. MesotheliomaNews.com is a public service of Baron & Budd, P.C.

© 2008, Baron & Budd, P.C.